Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.27 | -0.05 | 0.07 | 0.51 |
| FCF Yield | -4.11% | -8.20% | -13.69% | -7.67% |
| EV / EBITDA | -17.56 | -6.57 | -7.82 | -5.58 |
| Quality | ||||
| ROIC | -14.71% | -13.63% | -9.07% | -8.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.68 | 1.45 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -15.54% | 32.05% | -67.32% | 2.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 1.06 | 1.42 | 3.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |